FDA Removes Eli Lilly’s Mounjaro and Zepbound from Shortage List Sparking Lawsuit from Compounders
XTalks
OCTOBER 10, 2024
While good news for users, the FDA decision sparked a heated response from the compounding pharmacy sector, which has filed a lawsuit against the agency claiming its actions were arbitrary and unlawful. During this time, compounding pharmacies were permitted to produce lower-cost versions of the injectable medications.
Let's personalize your content